Overweight and Obesity Determine the Risk for Gastrointestinal Cancer in a Sex-Dependent Manner: A Retrospective Cohort Study of 287,357 Outpatients in Germany.
BMI
body mass index
colon cancer
epidemiology
fat
tumor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Feb 2022
13 Feb 2022
Historique:
received:
27
01
2022
revised:
08
02
2022
accepted:
11
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Cancer represents the second leading cause of death worldwide, implementing a major health care and socioeconomic burden. Overweight and obesity, both of which are dramatically on the rise in both highly and less developed regions worldwide, have been established as modifiable risk factors for the development of various tumor entities including gastrointestinal (GI) cancers such as colorectal or gastric cancer. However, systematic data on an association between excessive body fat and GI cancer development from Germany are missing. A total of 287,357 adult outpatients with an available BMI value between 2010 and 2019 were identified from the Disease Analyzer database (IQVIA). The main outcome was the association between pre-obesity (BMI 25-30 kg/m Within the observation period, the proportion of colon cancer patients increased stepwise from 0.5% and 0.64% in normal weight to 0.71% and 0.91% in obese female and male patients, respectively, which was confirmed in multivariable regression models (OR Our data suggest that obesity represents a decisive risk factor for the development of colon, rectal, and liver cancer, partly in a sex-dependent manner. Since overweight and obesity are modifiable risk factors, the current results may help to establish appropriate prevention and lifestyle programs to reduce both the incidence as well as the high morbidity and mortality of GI tumors in the future.
Identifiants
pubmed: 35205678
pii: cancers14040931
doi: 10.3390/cancers14040931
pmc: PMC8869970
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Hepatol. 2022 Jan;76(1):247-248
pubmed: 34520785
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499223
Cancers (Basel). 2021 May 06;13(9):
pubmed: 34066328
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Int J Mol Sci. 2021 Sep 10;22(18):
pubmed: 34575947
Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724
pubmed: 33559592
J Cancer Res Clin Oncol. 2021 Dec 12;:
pubmed: 34897572
Cancer Metastasis Rev. 2021 Mar;40(1):31-46
pubmed: 33009650
Diagnostics (Basel). 2021 Jul 26;11(8):
pubmed: 34441278
Int J Cancer. 2011 Oct 1;129(7):1708-17
pubmed: 21105029
Cytokine. 2013 Dec;64(3):626-37
pubmed: 24120848
Nat Rev Endocrinol. 2021 Jun;17(6):350-363
pubmed: 33927368
Eur J Cancer. 2012 Sep;48(14):2137-45
pubmed: 22446023
Hepatol Commun. 2020 Jun 22;4(9):1293-1301
pubmed: 32923833
Medicine (Baltimore). 2020 Dec 11;99(50):e23436
pubmed: 33327272
Cent Eur J Public Health. 2021 Mar;29(1):38-44
pubmed: 33831285
J Neurogastroenterol Motil. 2021 Jul 30;27(3):314-325
pubmed: 33762473
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Nat Commun. 2018 Aug 28;9(1):3490
pubmed: 30154431
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
Front Endocrinol (Lausanne). 2021 Sep 06;12:706978
pubmed: 34552557
Curr Obes Rep. 2021 Jun;10(2):100-115
pubmed: 33523397
Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1395-408
pubmed: 23697611
Asian Pac J Cancer Prev. 2015;16(10):4161-8
pubmed: 26028066
Front Oncol. 2021 Mar 30;11:638918
pubmed: 33859943
Metabolism. 2019 Mar;92:121-135
pubmed: 30445141
Cancer Res. 2001 Jan 1;61(1):126-30
pubmed: 11196149
J Cancer Res Clin Oncol. 2021 Dec 12;:
pubmed: 34897573
Cancer Causes Control. 1997 Mar;8(2):146-58
pubmed: 9134238